The scenario is very different in India and the US. Firstly, because the availability of next generation sequencing platforms is still restricted in India as compared to the US and also because of the high cost of running these platforms. The quantum of data generation is much lower in India.

High levels of data generation and analyses provide greater experience in handling such data, resulting in increase in expertise. Further, the community of scientists engaged in next generation sequencing R&D is much smaller in India compared to that in the US. Therefore, there is very little scope of dialogue and argumentation on NGS. This has restricted the development of expertise in India.

What are your future plans?

Our future plans are to continue-to-contribute towards the understanding of genetic factors that are underlying human diseases, especially those that are of public health importance in India.